Gorelov V G, Gorodetskiĭ V M, Shulutko E M, Zil'ber K I
Ter Arkh. 1994;66(7):17-20.
The authors review pulmonary effects achieved for 3 years in hemoblastosis patients subjected to artificial lung ventilation (ALV). Out of 44 patients treated the response to ALV was obtained in 7 (16%). Prior to ALV, two of them had granulocyte count under 0.5 x 10(-9)/1. ALV was discontinued in them after recovery of normal granulocyte count. Three patients (7%) survived 6 months and longer. Problems of differential diagnosis in different variants of acute respiratory failure in hemoblastosis patients and ALV potentialities are discussed.
作者回顾了接受人工肺通气(ALV)的血液病患者3年期间的肺部效应。在接受治疗的44例患者中,7例(16%)对ALV有反应。在进行ALV之前,其中2例患者的粒细胞计数低于0.5×10⁻⁹/L。粒细胞计数恢复正常后,他们停止了ALV。3例患者(7%)存活了6个月及更长时间。文中讨论了血液病患者急性呼吸衰竭不同变体的鉴别诊断问题以及ALV的潜力。